Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD I MARCUS

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1841451937
CMS profile
310960
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$18,634.29

172 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $9,500.00 4
Consulting Fee $5,423.75 5
Food and Beverage $3,710.54 163

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD I MARCUS

NPI 1841451937 · CMS profile ID 310960

Allopathic & Osteopathic Physicians / Ophthalmology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841451937?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD I MARCUS, NPI 1841451937, CMS profile ID 310960. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841451937?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). EDWARD I MARCUS, NPI 1841451937, CMS profile ID 310960. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841451937?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
EDWARD I MARCUS, NPI 1841451937, CMS profile ID 310960, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1841451937?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

172 matching records · $18,634.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 172 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 172.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $19.8905/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927272751 CMS
Genentech USA, Inc. $18.1505/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950776205 CMS
Alimera Sciences, Inc. $19.5605/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896601387 CMS
EyePoint Pharmaceuticals US, Inc. $15.0805/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932989907 CMS
Regeneron Healthcare Solutions, Inc. $565.0005/20/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927272735 CMS
Regeneron Healthcare Solutions, Inc. $423.7505/20/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927272741 CMS
Regeneron Healthcare Solutions, Inc. $565.0005/20/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927272745 CMS
Bausch & Lomb Americas Inc. $23.7005/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957478067 CMS
Novartis Pharmaceuticals Corporation $18.8505/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893936873 CMS
Mallinckrodt Hospital Products Inc. $25.2105/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937511311 CMS
Genentech USA, Inc. $27.7205/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950777963 CMS
EyePoint Pharmaceuticals US, Inc. $7.3105/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932989911 CMS
EyePoint Pharmaceuticals US, Inc. $13.5605/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932994917 CMS
Novartis Pharmaceuticals Corporation $23.8105/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893936865 CMS
Novartis Pharmaceuticals Corporation $10.1205/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893936869 CMS
ABBVIE INC. $17.7205/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891096763 CMS
EyePoint Pharmaceuticals US, Inc. $17.7805/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932994889 CMS
Alimera Sciences, Inc. $20.5105/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896601491 CMS
EyePoint Pharmaceuticals US, Inc. $18.1005/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932990263 CMS
EyePoint Pharmaceuticals US, Inc. $7.9205/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932991897 CMS
Mallinckrodt Hospital Products Inc. $19.2404/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937511307 CMS
Mallinckrodt Hospital Products Inc. $2.6504/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937511309 CMS
Mallinckrodt Hospital Products Inc. $5.5104/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937511305 CMS
ABBVIE INC. $19.7504/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891096761 CMS
ABBVIE INC. $6.0204/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891096759 CMS
Alimera Sciences, Inc. $20.7504/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896601489 CMS
Regeneron Healthcare Solutions, Inc. $23.6104/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927272731 CMS
Genentech USA, Inc. $21.1204/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950782577 CMS
EyePoint Pharmaceuticals US, Inc. $24.5004/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932991909 CMS
Alimera Sciences, Inc. $118.5304/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896606041 CMS
EyePoint Pharmaceuticals US, Inc. $12.7204/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932989915 CMS
Alimera Sciences, Inc. $19.6604/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896601317 CMS
Genentech USA, Inc. $19.6004/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950789489 CMS
Novartis Pharmaceuticals Corporation $22.9203/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893936861 CMS
EyePoint Pharmaceuticals US, Inc. $24.7803/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932994913 CMS
EyePoint Pharmaceuticals US, Inc. $3.5103/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932990259 CMS
EyePoint Pharmaceuticals US, Inc. $11.8103/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932991917 CMS
EyePoint Pharmaceuticals US, Inc. $4.2203/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932994881 CMS
Regeneron Healthcare Solutions, Inc. $25.3603/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927272725 CMS
Alimera Sciences, Inc. $16.5503/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896601509 CMS
Mallinckrodt Hospital Products Inc. $6.7503/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937511301 CMS
Mallinckrodt Hospital Products Inc. $17.0803/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937511303 CMS
Alimera Sciences, Inc. $21.2603/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896601507 CMS
EyePoint Pharmaceuticals US, Inc. $10.0003/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932989923 CMS
ABBVIE INC. $22.7003/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891096757 CMS
Mallinckrodt Hospital Products Inc. $15.9603/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937511299 CMS
EyePoint Pharmaceuticals US, Inc. $7.6403/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932989919 CMS
Genentech USA, Inc. $24.3003/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950792471 CMS
EyePoint Pharmaceuticals US, Inc. $19.3903/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932991901 CMS
Alcon Vision LLC $99.8403/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905041603 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12,406.33 87
PY2020 $14,333.12 96
PY2021 $16,148.36 158
PY2022 $18,634.29 172
PY2023 $16,549.63 209
PY2024 $40,447.08 256
PY2025 $34,756.22 215

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $31,438.00 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Astellas Pharma Global Development $573.00 11/24/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186086
Principal investigator 1 Astellas Pharma Global Development $831.00 11/24/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186090
Principal investigator 1 Astellas Pharma Global Development $573.00 11/03/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186082
Principal investigator 1 Astellas Pharma Global Development $573.00 11/03/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186084
Principal investigator 1 Astellas Pharma Global Development $573.00 11/03/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,062.00 10/10/2025 Non-covered Recipient Entity
SIGHT MEDICAL DOCTORS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184249769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,793.00 10/10/2025 Non-covered Recipient Entity
SIGHT MEDICAL DOCTORS PLLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184249771
Principal investigator 1 Astellas Pharma Global Development $1,675.00 10/02/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186092
Principal investigator 1 Astellas Pharma Global Development $1,675.00 08/14/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186072
Principal investigator 1 Astellas Pharma Global Development $1,675.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186064
Principal investigator 1 Astellas Pharma Global Development $1,675.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186066
Principal investigator 1 Astellas Pharma Global Development $573.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186068
Principal investigator 1 Astellas Pharma Global Development $573.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186070
Principal investigator 1 Astellas Pharma Global Development $1,675.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186074
Principal investigator 1 Astellas Pharma Global Development $573.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186076
Principal investigator 1 Astellas Pharma Global Development $7,793.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186078
Principal investigator 1 Astellas Pharma Global Development $573.00 08/11/2025 Non-covered Recipient Entity
Sight Medical Doctors PLLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234186080